Cargando…
Racial Differences in Androgen Receptor (AR) and AR Splice Variants (AR-SVs) Expression in Treatment-Naïve Androgen-Dependent Prostate Cancer
Androgen receptor splice variants (AR-SVs) contribute to the aggressive growth of castration-resistant prostate cancer (CRPC). AR-SVs, including AR-V7, are expressed in ~30% of CRPC, but minimally in treatment-naïve primary prostate cancer (PCa). Compared to Caucasian American (CA) men, African Amer...
Autores principales: | Khan, Farhan, Anelo, Obianuju Mercy, Sadiq, Qandeel, Effah, Wendy, Price, Gary, Johnson, Daniel L., Ponnusamy, Suriyan, Grimes, Brandy, Morrison, Michelle L., Fowke, Jay H., Hayes, D. Neil, Narayanan, Ramesh |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10044992/ https://www.ncbi.nlm.nih.gov/pubmed/36979627 http://dx.doi.org/10.3390/biomedicines11030648 |
Ejemplares similares
-
Destroying the androgen receptor (AR)-potential strategy to treat advanced prostate cancer
por: Narayanan, Ramesh, et al.
Publicado: (2017) -
Therapeutic targeting of the androgen receptor (AR) and AR variants in prostate cancer
por: Narayanan, Ramesh
Publicado: (2020) -
Diverse roles of androgen receptor (AR) domains in AR-mediated signaling
por: Claessens, Frank, et al.
Publicado: (2008) -
Identification of an AR Mutation-Negative Class of Androgen Insensitivity by Determining Endogenous AR Activity
por: Hornig, N. C., et al.
Publicado: (2016) -
Baicalein suppresses the androgen receptor (AR)-mediated prostate cancer progression via inhibiting the AR N-C dimerization and AR-coactivators interaction
por: Xu, Defeng, et al.
Publicado: (2017)